Medpace CEO sells 650 shares at $620 average

Q: What insider transaction did MEDP report for August J. Troendle on this Form 4?

The filing reports that August J. Troendle sold 650 MEDP common shares on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected under a limit order during an open window period.

Q: How many MEDP shares does August J. Troendle hold directly after this transaction?

After the reported sale, August J. Troendle directly holds 539,894 shares of Medpace Holdings, Inc. common stock, according to the Form 4 disclosure.

Q: What indirect MEDP holdings are associated with Medpace Investors, LLC?

Medpace Investors, LLC holds 4,733,019 MEDP shares. August J. Troendle is the sole manager and controlling unit holder, with sole voting and investment control, and may be deemed to indirectly beneficially own those shares while disclaiming beneficial ownership except for his pecuniary interest.

Q: What price range applied to the MEDP shares sold by August J. Troendle?

The Form 4 states the reported price of $620.27 is a weighted average price. The 650 shares were sold in multiple transactions with prices ranging from $620.00 to $621.28 per share.

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold 650 shares of common stock on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected pursuant to a limit order during an open window period.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold 650 shares of common stock on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected pursuant to a limit order during an open window period. After this sale, he directly holds 539,894 shares. He is also the sole manager and controlling unit holder of Medpace Investors, LLC, which holds 4,733,019 shares; he may be deemed to indirectly beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Seller: 650 shares

Net Sell 2 txns

Insider Troendle August J.

Role President & CEO

Sold 650 shs ($403K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	650	$620.27	$403K
holding	Common Stock ^F3	--	--	--

Holdings After Transaction: Common Stock — 539,894 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)

Footnotes (3)

F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.28. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
F3. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Key Figures

Shares sold: 650 shares of Common Stock Weighted average sale price: $620.27 per share Direct holdings after transaction: 539,894 shares +2 more

5 metrics

Shares sold 650 shares of Common Stock Sale on 2026-08-27 by President & CEO August J. Troendle

Weighted average sale price $620.27 per share Weighted average for multiple sale transactions ranging from $620.00 to $621.28

Direct holdings after transaction 539,894 shares Common Stock directly owned by August J. Troendle following the 2026-08-27 sale

Indirect holdings via Medpace Investors, LLC 4,733,019 shares Common Stock held by Medpace Investors, LLC over which Troendle has sole voting and investment control

Net buy/sell shares 650 shares net sold Net insider trading activity in this Form 4, classified as net-sell

Key Terms

limit order, weighted average price, indirectly beneficially own, pecuniary interest

4 terms

limit order market

"effected pursuant to a limit order placed by the Reporting Person"

A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.

weighted average price financial

"The reported price is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirectly beneficially own financial

"may be deemed to indirectly beneficially own the securities"

pecuniary interest financial

"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MEDP report for August J. Troendle on this Form 4?

The filing reports that August J. Troendle sold 650 MEDP common shares on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected under a limit order during an open window period.

How many MEDP shares does August J. Troendle hold directly after this transaction?

After the reported sale, August J. Troendle directly holds 539,894 shares of Medpace Holdings, Inc. common stock, according to the Form 4 disclosure.

What indirect MEDP holdings are associated with Medpace Investors, LLC?

Medpace Investors, LLC holds 4,733,019 MEDP shares. August J. Troendle is the sole manager and controlling unit holder, with sole voting and investment control, and may be deemed to indirectly beneficially own those shares while disclaiming beneficial ownership except for his pecuniary interest.

Was the MEDP insider sale made under a Rule 10b5-1 trading plan?

The Form 4 indicates the document-level Rule 10b5-1 checkbox is not marked. A footnote states the transactions were effected pursuant to a limit order placed during an open window period, not describing them as made under a Rule 10b5-1 plan.

What price range applied to the MEDP shares sold by August J. Troendle?

The Form 4 states the reported price of $620.27 is a weighted average price. The 650 shares were sold in multiple transactions with prices ranging from $620.00 to $621.28 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 04:12 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last)

(First)

(Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI

OHIO

45227

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/27/2026		S⁽¹⁾		650	D	$620.27⁽²⁾	539,894	D
Common Stock								4,733,019	I	By Medpace Investors, LLC⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $621.28. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR